Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 6, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 11.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 6, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| January 15, 2027 | Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant | Trial Milestone | Phase 1/Phase 2 |
| March 15, 2029 | Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation | Trial Milestone | Phase 3 |
| December 15, 2029 | Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients | Trial Milestone | Phase 2 |
Track ELDN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ELDN in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 13, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 13, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 19, 2026 | Quarterly results filed (8-K) | Earnings | — |
| November 14, 2025 | Quarterly results filed (8-K) | Earnings | — |
| November 13, 2025 | 8-K filed: Material agreement | Corporate | — |
| November 7, 2025 | Quarterly results filed (8-K) | Earnings | — |
| September 11, 2025 | Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation | Trial Milestone | Phase 2 |
| August 14, 2025 | Quarterly results filed (8-K) | Earnings | — |
| August 6, 2025 | 8-K filed: Reg FD disclosure | Filing | — |
| May 14, 2025 | Quarterly results filed (8-K) | Earnings | — |
| July 31, 2023 | Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) | Trial Milestone | Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.